As part of our mission to support patients on a global scale, Nabriva is providing a Named Patient Program (NPP) to supply XENLETA® (lefamulin) to Healthcare Professionals (HCPs) in certain countries where XENLETA is not yet available.

The NPP is designed to ensure that physicians can request IV or oral XENLETA on behalf of patients who meet the necessary eligibility criteria and who live in certain countries where it is not yet available.

Nabriva has partnered with WEP Clinical, a UK-based pharmaceutical services company, to provide this program.  Under the terms of the NPP, XENLETA will be made available to patients in two formulations - 150mg injection for intravenous administration and 600mg oral tablets.  WEP Clinical is authorized to distribute XENLETA on a named patient basis but is not involved in the patient-doctor relationship. WEP Clinical is only permitted to distribute in response to an unsolicited physician request which has been reviewed and meets the necessary eligibility criteria.  Once a request is approved, WEP Clinical will manage the distribution of XENLETA to the treating physician and will provide any necessary follow-up support and services. 

For further information on the XENLETA Named Patient Program, please contact:

XENLETA NPP Contact Number: +44 207 887 2235

XENLETA NPP Email Address: xenletaNPP@wepclinical.com